Navigation Links
Clinical Force Announces that Stiris Research has Selected the Clinical Force CTMS to Manage Clinical Trials
Date:10/15/2009

//www.clinicalforce.com/page.asp?pageID=83&bewrpstr" onclick="linkClick( this.href );" target="_blank" title="monitoring report">monitoring report and follow-up letter generation - saving time and cost
Stiris' President Shantal Feltham states it was Clinical Force's innovative implementation approach that led to the CTMS choice. "Stiris is an organization based on a team approach, commitment to service, and innovative problem solving for our clients. Clinical Force brought the same attributes to the CTMS implementation and proved to be the best fit for us and our clients. As Stiris grows, we look forward to offering our clients this expanded service while maintaining cost efficiencies."

Keep up to date on the Stiris Research CTMS project through this webpage. Stiris CTMS Project Status

About Clinical Force

Clinical Force delivers a best in class Clinical Trial Management System (CTMS) to Clinical Research Organizations (CROs) and Sponsors in North and South America, Europe and Africa. Clinical Force customers are successfully using the CTMS to improve their clinical trial execution, saving time and money. As the industry's first SaaS CTMS provider, Clinical Force has the most advanced SaaS solution and the most experience implementing and supporting the SaaS model. The SaaS model benefits Clinical Force customers with rapid and simple installation and a remarkably affordable total cost of ownership. Clinical Force is a rapidly growing, privately held company with strong life science pedigree. To stay close to our customers, Clinical Force has offices in the US and Europe. www.clinicalforce.com

About Stiris Research
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ... Therapy Market, 2015 - 2025" report to their ... report provides an extensive study on the marketed and ... carried out in this field for over a decade ... in Asian markets; one approved in the EU). There ...
(Date:3/3/2015)... Clara, California (PRWEB) March 03, 2015 ... development service company, has launched a new Life Science ... reagents for preclinical research. , The first products ... antibody isotype controls, and soon to be released in ... company will continue to expand their life science portfolio ...
(Date:3/3/2015)... Md. , March 3, 2015  RegeneRx Biopharmaceuticals, ... editorial in the scientific journal, Expert Opinion on ... his colleague, Dr. Zhenggang Zhang , at the ... reported that Thymosin beta 4 (TB4) has the ... remodeling 24 hours or more post-injury, leading to neurological ...
(Date:3/3/2015)... Liberty Corner, New Jersey (PRWEB) March 03, 2015 ... in NJ, has announced today that it has ... DE. Terms of the transaction were not ... engineering consulting services to the energy sector including ... gas, alternative energy, and fossil and nuclear power ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Jim Slevin Joins from CV Therapeutics as Senior Director ... Management, Integrated Healthcare ... a medical,technology company committed to the development and commercialization ... hired Jim,Slevin to serve as the Senior Director of ...
... 8 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... of Directors, effective,October 4, 2007. The Company also announced that ... October 3, 2007. Mr. Zilkha is a Principal at ... of the Health Care industry team. Prior to joining KKR,earlier ...
... chronic bronchitis patients to benefit from rapid, long-lasting symptom ... ... formoterol fumarate -, NAPA, Calif., Oct. 8 ... today announced the launch of Perforomist(TM),(formoterol fumarate) Inhalation Solution, which ...
Cached Biology Technology:Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device 2Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 2Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 3Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 4Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 5Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD 6
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... is giving the VIP treatment to laboratory mice in ... , VIP is not "very important person," but vasoactive ... gut, that is also made by a specialized group ... Washington University assistant professor of Biology in Arts & ...
... the genes, cancer is always rooted in genetic errors ... of the first genetic triggers for cancer as mutations ... and metastatic cancers, however, often exhibit many genetic mutations, ... question, and one with significant clinical implications, has been ...
... clones of cells from existing human embryonic stem cells. The ... and spinal cord injury. , "This cloning of cells involves ... extracting and then growing a single cell," said UNSW Senior ... is based at the Diabetes Transplant Unit (DTU) at the ...
Cached Biology News:Discovery clarifies role of peptide in biological clock 2Unchecked DNA replication drives earliest steps toward cancer 2Unchecked DNA replication drives earliest steps toward cancer 3Stem cell research - new cell lines 2
... a preparation of deoxyribonuclease I that ... produce 3-hydroxyl oligonucleotides. This preparation is ... maintaining the integrity of RNA is ... use with the Core Footprinting System ...
...
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
RNase-Free DNase 50 l...
Biology Products: